Literature DB >> 12721159

Stimulated intra-uterine insemination is not a natural choice for the treatment of unexplained subfertility. Should the guidelines be changed?

Jane A Stewart1.   

Abstract

The Royal College of Obstetricians and Gynaecologists Guidelines for the management of infertility in secondary care (1998) states that stimulated intrauterine insemination (IUI) has Grade A evidence to confirm its effective use in unexplained infertility. This paper challenges that assertion after closer assessment of the papers upon which it was based. With the current appraisal of the Guidelines as part of the 'scope' of the assessment of infertility management by the National Institute of Clinical Excellence it is important that the guidelines are indeed critically reviewed prior to their updated publication. With the emphasis on minimizing the risk of multiple pregnancies, a formal trial of stimulated IUI is called for in order to justify its continued use in this setting. Strict attention to limiting the number of follicles treated in verified unexplained subfertility is necessary to validate such a trial.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721159     DOI: 10.1093/humrep/deg237

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  3 in total

1.  Intra-uterine insemination for unexplained subfertility.

Authors:  Reuben Olugbenga Ayeleke; Joyce Danielle Asseler; Ben J Cohlen; Susanne M Veltman-Verhulst
Journal:  Cochrane Database Syst Rev       Date:  2020-03-03

2.  Acceptable pregnancy rate of unstimulated intrauterine insemination: a retrospective analysis of 17,830 cycles.

Authors:  Tetsuro Honda; Mai Tsutsumi; Fumio Komoda; Kenichi Tatsumi
Journal:  Reprod Med Biol       Date:  2014-08-21

3.  Minimal stimulation using gonadotropin combined with clomiphene citrate or letrozole for intrauterine insemination.

Authors:  Bo Hyon Yun; Seung Joo Chon; Joo Hyun Park; Seok Kyo Seo; SiHyun Cho; Young Sik Choi; Seok Hyun Kim; Byung Seok Lee
Journal:  Yonsei Med J       Date:  2015-03       Impact factor: 2.759

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.